Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, June 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2022 (2022-06-30): -3.17%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
EUDA Health Holdings Limited
Market Cap
$36.21M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$35.84M
Return on Equity (ROE)
-476.77%
TTM Avg
-979.99%
3Y Avg
-646.46%
5Y Avg
-421.61%
Market Cap
$35.84M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$35.76M
Return on Equity (ROE)
-161.63%
TTM Avg
-60.21%
3Y Avg
-26.37%
5Y Avg
-20.13%
Market Cap
$35.52M
Return on Equity (ROE)
-819.34%
TTM Avg
-116.46%
3Y Avg
-74.90%
5Y Avg
-96.78%
Market Cap
$34.97M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$37.93M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$34.35M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
Market Cap
$38.61M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EUDA Health Holdings Limited (EUDA) | $36.21M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | -476.77% | -979.99% | -646.46% | -421.61% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | -160.05% | -184.57% | -168.71% | -141.15% |
| DocGo Inc. (DCGO)vs › | $35.76M | -161.63% | -60.21% | -26.37% | -20.13% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | -819.34% | -116.46% | -74.90% | -96.78% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | -154.06% | -1.75% | 68.54% | 60.27% |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | -28.65% | -189.41% | -194.44% | -158.64% |
| Elutia Inc (ELUT)vs › | $34.35M | 329.02% | 154.76% | 265.18% | 128.71% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | -140.36% | -216.21% | -112.57% | -76.80% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $38.78M | -83.03% | -44.32% | 5.07% | 17.23% |
ROE
N/A
ROA
-277.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-06-30 | -3.17% |
| 2022-03-31 | -0.90% |
| 2021-12-31 | -53.50% |
